Hormonal Disorders


Parathyroidectomy Can Reduce Adverse Outcomes Risk in Primary Hyperparathyroidism

June 20, 2022

Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.

TLANDO, an Oral Option for TRT for Men, Approved by US FDA

March 29, 2022

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.